Nanoparticles and their Therapeutic Applications in Pharmacy

DOI:

https://doi.org/10.37285/ijpsn.2014.7.3.2

Authors

  • A.P. Gadad
  • Vijay Kumar S M
  • P M Dandagi
  • U B Bolmol
  • N. Pavani Pallavi

Abstract

Nanotechnology is providing solutions several pharma-ceutical drug delivery issues. With the emergence of nanotechnology, researchers become more interested in studying the unique properties of nanoscale materials. Nanoparticles are attractive tool in pharmaceutical and biomedical fields. These particulate systems have been used as a physical approach to alter and improve the pharmacokinetic and pharmacodynamic properties of various types of drug/proteins. Nanoparticles have been used in-vivo to protect the drug/proteins molecules in the systemic circulation, targeting of the drug to the chosen sites and to deliver the drug at a controlled and sustained rate to the site of action. Various types polymers have been used in the formulation of nanoparticles for drugs, proteins, and hormone delivery are discussed in this article. It also describes various methods of preparation, advantages, disadvantages and their applications in biomedical fields. It provides an overview of characterization of nanoparticles, storage, and commercially available nanoformulations.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Keywords:

Nanosuspension, Preparations, Storage, Characterization, Nano-applications

Downloads

Published

2014-08-31

How to Cite

1.
Gadad A, S M VK, Dandagi PM, Bolmol UB, Pallavi NP. Nanoparticles and their Therapeutic Applications in Pharmacy. Scopus Indexed [Internet]. 2014 Aug. 31 [cited 2024 May 18];7(3):2509-1. Available from: http://www.ijpsnonline.com/index.php/ijpsn/article/view/720

Issue

Vol. 7 No. 3 (2014): July-September 2014

Section

Review Articles
Crossref
Scopus
Google Scholar
Europe PMC

References

Adibkia K, Reza M, Shadbad S, Nokhodchi A, Javadzedeh A, Jalali MB, Barar J, Mohammadi G, and Omidi Y (2007). Piroxicam nanoparticles for ocular delivery: physicochemical characterization and implementation in endotoxin-induced uveitis. J Drug Target 15(6): 407-16.

Alexis F et al., (2008). Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol. Pharm 5(4): 505-515.

Ammoury N, Fessi H, Devissaguet J-P, Dubrasquet M, Benita S (1991). Jejunal absorption, pharmacological activity, and pharmacokinetic evaluation of indomethacin-loaded poly(d,l-lactide) and poly(isobutylcyanoacrylate) nanocapsules in rats. Pharm Res 8: 101-5.

Barichello JM, Morishita M, Takayama K, Nagai T (1999). Encapsulation of hydrophilic and lipophilic drugs in PLGA nanoparticles by the nanoprecipitation method. Drug Dev Ind Pharm 25: 471- 6.

Bhatt N, Ganesh B and Preeti K (2013). Drug delivery to the brain using polymeric nanoparticles: a review. Int J Pharm Life Sci 2(3): 2305-30

Bouchemal K, Briancon S, Perrier E, Fessi H, Bonnet I, Zydowicz N (2004). Synthesis and characterization of polyurethane and poly(ether urethane) nanocapsules using a new technique of interfacial polycondensation combined to spontaneous emulsification. Int J Pharm 269: 89-100.

Brandtzaeg P, Berstad A, Farstad I, Haraldsen G, Helgeland L, Jahnsen F, Johansen F, Natvig I, Nilsen E, Rugtveit J (1997). Mucosal immunity – a major adaptive defense mechanism. Behring Inst Mitt 98: 1-23.

Calvo P, Remunan LC, Vila JJL, Alonso MJ (1997). Novel hydrophilic chitosan-polyethylene oxide nanoprticles as protein carriers. J Appl Polymer Sci 63: 125-132.

Calvo P, Remunan LC, Vila JJL, Alonso MJ (1997). Chitosan and chitosan/ethylene oxide-propylene oxide block copolymer nanoparticles as novel carriers for proteins and vaccines. Pharm Res. 14: 1431-6.

Catarina PR, Ronald JN, Antonio JR, Francisco V (2006). Methods for preparation of drug-loaded polymeric nanoparticles. Nanomedicine: Nanotechnology, Biology, and Medicine 2: 8-21.

Charles SW, Popplewell J (1986). Properties and applications of magnetic liquid. Hand Book of Magnetic Materials. 2: 153.

Chingunpituk J (2007). Nanosuspension Technology for Drug Delivery. Walailak J Sci & Tech 4(2): 139-153.

Couvreur P, Barrat G, Fattal E, Legrand P, Vauthier C (2002). Nanocapsule technology. Crit Rev Ther Drug Carrier Syst 19: 99- 134.

Couvreur P, Kante B, Lenaerts V, Scailteur V, Roland M, Speiser P (1980). Tissue distribution of antitumour drugs associated with polyalkylcyanoacrylate nanoparticles. J Pharm Sci 69: 199-202.

Damge C, Michel C, Aprahamian M, Couvreur P, Devissaguet JP (1990). Nanocapsules as carriers for oral peptide delivery. J. Control. Release 13: 233-239.

Esquisabel A, Herna´ndez RM, Igartua M, Gasco´ n AR, Calvo B, Pedraz JL (1997). Production of BCG alginate-PLL microcapsules by emulsification/internal gelation. J Microencapsul 14: 627-38.

Fassas A et al., (2003). Safety of high-dose liposomal Daunorubicin (Daunoxome) for refractory or relapsed acute myeloblastic leukaemia. Br J Haematol 122(1): 161-163.

Feng SS (2004). Nanoparticles of biodegradable polymers for new-concept chemotherapy. Expert Rev. Med. Devices. 1(1): 115-125.

Fessi H, Puisieux F, Devissaguet JP, Ammoury N, Benita S (1989). Nanocapsule formation by interfacial deposition following solvent displacement. Int J Pharm 55: R1- R4.

Gqrsoy A, Eroglu L, Ulutin S, Tasyqrek M, Fessi H, Puisieux F, et al., (1989). Evaluation of indomethacin nanocapsules for their physical stability and inhibitory activity on inflammation and platelet aggregation. Int J Pharm 52: 101-8.

Jain AK, Nitin KS, Manasmita D, Chandraiah Go, Raman PS, Rama Rao P and Sanyog Jain (2011). Augmented Anticancer Efficacy of Doxorubicin-Loaded Polymeric Nanoparticles after Oral Administration in a Breast Cancer Induced Animal Model. Mol. Pharmaceutics 8: 1140-51.

Jain AK, Nitin KS, Chandraiah G, Raman PS, Sanyog J (2011). The effect of the oral administration of polymeric nanoparticles on the efficacy and toxicity of tamoxifen. Biomaterials. 32: 503-515.

Jung T, Kamm W, Breitenbach A, Kaiserling E, Xiao JX, Kissel T (2000). Biodegradable nanoparticles for oral delivery of peptides: Is there a role for polymers to affect mucosal uptake. Eur J Pharm Biopharm 50: 147-60.

Jean-Christophe Y et al., (1996). Biodegradable nanoparticles-from sustained release formulations to improved site specific drug delivery. J. Control. Release 39: 339.

Khouri N, Roblot TL, Fessi H, Devissaguet JP, Puisieux F (1986). Development of a new process for the manufacture of polyisobutylcyanoacrylate nanocapsules. Int J Pharm 28: 125- 32.

Kipp JE, Wong JCT, Doty MJ and Rebbeck CL. Micro precipitation method for preparing submicron suspensions. US Patent 6,607,784 2003.

Kohli AK and Alpar HO (2004). Potential use of nanoparticles for transcutaneous vaccine delivery: Effect of particle size and charge. Int. J. Pharm. 275: 13-7.

Krause HJ, Schwarz A, Rohdewald P (1986). Interfacial polymerization, an useful method for the preparation of polymethylcyanoacrylate nanoparticles. Drug Dev Ind Pharm 12: 527-52.

Kreuter J (1982). The mechanism of termination in heterogeneous polymerization. J Polym Sci 20: 543-5.

Kreuter J, Speiser P (1976). New adjuvants on a polymethyl (methacrylate) base. Infect Immun 13: 204-10.

Kreutera J et al., (1997). Influence of the type of surfactant on the analgesic effects induced by the peptide dalargin after its delivery across the blood–brain barrier using surfactant-coated nanoparticles. J Control Rel 49: 81.

Kumar PS, et al., (2006). Influence of microencapsulation method and peptide loading on formulation of poly(lactide-co-glycolide) insulin nanoparticles. Pharmazie. 61(7): 613-617.

Kumar N, Ravikumar MNV, Domb AJ (2001). Biodegradable block copolymers. Adv Drug Deliv Rev 53: 23-44.

Lee V, Yamamoto A (1990). Penetration and enzymatic barriers to peptide and protein absorption. Adv.Drug Deliv. Rev. 4: 171-207.

Li VHK, Wood RW, Kreuter J, Harmia T, Robinson JR (1986). Ocular drug delivery of progesterone using nanoparticles. J Microencapsul 3: 213-8.

Li YZ, Sun X, Gong T, Liu J, Zuo J, Zhang ZR (2010). Inhalable microparticles as carriers for pulmonary delivery of thymopentin-loaded solid lipid nanoparticles. Pharm Res 27: 1977-1986.

Matsumoto J et al., (1999). Preparation of nanoparticles consisted of poly(lactide)–poly(ethylene glycol)–poly(l-lactide) and their evaluation in vitro. Int. J. Pharm. 185(1): 93-101.

Mittal G et al., (2007). Estradiol loaded PLGA nanoparticles for oral administration: effect of polymer molecular weight and copolymer composition on release behavior in vitro and in vivo. J. Control. Release. 119(1): 77-85.

Montasser I, Fessi H, Coleman AW (2002). Atomic force microscopy imaging of novel type of polymeric colloidal nanostructures. Eur J Pharm Biopharm 54: 281-4.

Mohanraj VJ and Chen Y (2006). Nanoparticles – A Review. Tropical J Pharm Res 5(1): 561-573.

Molpeceres J, Aberturas MR, Guzman M (2000). Biodegradable nanoparticles as a delivery system for cyclosporine: preparation and characterization. J Microencapsul. 17: 599-614.

Molpeceres J, Guzman M, Aberturas MR, Chacon M, Berges L (1996). Application of central composite designs to the preparation of polycaprolactone nanoparticles by solvent displacement. J Pharm Sci 85: 206-13.

Muhlen AZ, Muhlen EZ, Niehus H, Mehnert W (1996). Atomic force microscopy studies of solid lipid nanoparticles. Pharm Res 13: 1411-16.

Mu L, Feng SS (2003). A novel controlled release formulation for the anticancer drug paclitaxel: PLGA nanoparticles containing vitamin E TPGS. J Control Release 86: 33-48.

Müller RH, Böhm BHL and Grau MJ (1999). Nanosuspensions-Formulations for poorly soluble drugs with poor bioavailability/2nd communication: Stability, biopharmaceutical aspects, possible drug forms and registration aspects. Pharm Ind 61: 175-8.

Nagavarma BVN, Hemant KSY, Ayaz, Vasudha LS, Shivakumar HG (2012). Different techniques for preparation of polymeric nanoparticles- a Review. Asian J Pharm Clin Res 3(5):16-23.

Nemati F, Dubernet C, Fessi H, Verdie`re AC, Poupon MF, Puisieux F, et al., (1996). Reversion of multidrug resistance using nanoparticles in vitro: influence of the nature of the polymer. Int J Pharm 138: 237- 46.

Panyam J, Zhou WZ, Prabha S, Sahoo SK, Labhasetwar V (2002). Rapid endo-lysosomal escape of poly(DL-lactide-co-glycolide) nanoparticles: implications for drug and gene delivery. Faseb J 16: 1217-26.

Patel M, Jain SK, Yadav AK, Gogna D, Agrawal GP (2006). Preparation and characterization of oxybenzone-loaded gelatin microspheres for enhancement of sunscreening efficacy. Drug Delivery 13(5): 323-330.

Patil AS, Deshapandde TD, Joshi PM, Gadad AP. Influence of organic solvents on nanoparticles loaded with gatifloxacin. U J Pharmacy 02(02): 95-101.

Perez C, Sa´nchez A, Putnam D, Ting D, Langer R, Alonso MJ (2001). Poly(lactic acid)-poly(ethylene glycol) nanoparticles as new carriers for the delivery of plasmid DNA. J Control Rel 75: 211-24.

Pignatello R, Ricupero N, Bucolo C, Maugeri F, Maltese A, Puglisi G (2006). Preparation and characterization of Eudragit retard nanosuspensions for the ocular delivery of cloricromene. AAPS PharmSciTech 7(1): 27.

Polakovic M, Gorner T, Gref R, Dellacherie E (1999). Lidocaine loaded biodegradable nanospheres. II. Modelling of drug release. J Control Rel 60: 169-177.

Quintanar-Guerrero D, Alle´mann E, Fessi H, Doelker E (1998). Preparation techniques and mechanism of formation of biodegradable nanoparticles from preformed polymers. Drug Dev Ind Pharm 24: 1113-28.

Radwan MA, Aboul-Enein HY (2002). The effect of the oral absorption enhancers on the in vivo performance of insulin-loaded poly(ethyl- cyanoacrylate) nanospheres in diabetic rats. J Microencapsul 19: 225-35.

Raghuvanshi RS et al., (2002). Improved immune response from biodegradable polymer particles entrapping tetanus toxoid by use of different immunization protocol and adjuvants. Int J Pharm 245(1-2): 109-121.

Rolland A, Gibassier D, Sado P, Le Verge R. Purification et proprie´te´s physicochimiques des suspensions de nanoparticules de polyme`re. J Pharm Belg 1986; 41: 94 - 105.

Sanyog J, Pankaj UV, Nitin KS and Kaushik T (2012). Gelatin Coated Hybrid Lipid Nanoparticles for Oral Delivery of Amphotericin B. Mol Pharmaceutics 9: 2542-53.

Shim J, HS Kang, W-S Park, S-H Han, J Kim and I-S Chang (2004). Transdermal delivery of mixnoxidil with block copolymer nanoparticles. J Control Rel 97: 477-84.

Sanyog J, Vishal V R, Amit KJ, Manasmita D and Chandraiah G (2012). Folate-decorated PLGA nanoparticles as a rationally designed vehicle for the oral delivery of insulin. Nanomedicine 7(9): 1311-37.

Safra T et al., (2000). Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m. Ann Oncol 11(8): 1029-1033.

Schroeder U et al., (1998). Nanoparticle technology for delivery of drugs across the blood–brain barrier. J Pharm Sci 87(11): 1305–07.

Soppimath KS, Aminabhavi TM, Kulkarni AR, Rudzinski WE (2001). Biodegradable polymeric nanoparticles as drug delivery devices. J Control Rel 70: 1-20.

Tice TR, Gilley RM (1985). Preparation of injectable controlled-release microcapsules by solvent-evaporation process. J Control Rel 2: 343-52.

Tobio M et al., (2003). The role of PEG on the stability in digestive fluids and in vivo fate of PEG–PLA nanoparticles following oral administration. Colloids Surf B: Biointerfaces 18(3-4): 315-323.

Trotta M, Gallarete M, Pattarino F and Morel S (2001). Emulsions containing partially water miscible solvents for the preparation of dry nanosuspensions. J Control Rel 76: 119-28.

Udupa N (2013). Exploring nanotechnology in healthcare. Manipal university publication.

Vauthier C, Dubernet C, Fattal E, Pinto-Alphandary H, Couvreur P (2003). Poly (alkyl cyanoacrylates) as biodegradable materials for biomedical applications. Adv Drug Deliv Rev 55: 519-48.

Vijaykumar N, Venkateswarlu V, Raviraj P (2012). Drug Nanoparticles-An Overview. 16: 111-132.

Vila A, Sanchez A, Tobio M, Calvo P, Alonso MJ (2002). Design of biodegradable particles for protein delivery. J Control Rel 78: 15-24.

Widder KJ, Flouret G, Senye A (1979). Magnetic microspheres: synthesis of a novel parenteral drug carrier. J Pharm Sci 68:79-82.

Wising SA, Muller RH (2003). Cosmetic applications for solid lipid nanoparticles (SLN). Int j pharm 254(01): 6-68.

Wright C, (1997). Micellar nanoparticles. US patent, number 5,620.021.

Yamaguchi Y et al., (2005) Successful treatment of photo-damaged skin of nano-scale at RA particles using a novel transdermal delivery. J Control Rel 104: 29-40.

Yoo HS, Oh JE, Lee KH, Park TG (1999). Biodegradable nanoparticles containing PLGA conjugate for sustained release. Pharm Res 16: 1114-8.

Yoshioka T, Hashida M, Muranishi S, Sezaki H (1981). Specific delivery of mitomycin C to the liver, spleen, and lung: nano- and microspherical carriers of gelatin. Int J Pharm 8: 131-41.

Zhang X, Xia Q and Gu N (2006). Preparation of all-trans retinoic acid nanosuspensions using a modified precipitation method. Drug. Dev. Ind. Pharm. 32: 857-63.

Zili Z, Sfar S and Fessi H (2005). Preparation and characterization of polycarprolactone nanoparticles containing griseofulvin. Int J Pharm 294: 261-67.